Evolus
EOLS
7.74
+0.36
+4.88%
Evolus
US · EOLS
#3736 by market cap
Listed 2018
7.74
+0.36
+4.88%
Live - 5344 symbols - heartbeat 290s ago
· 2026-10-08 08:55
Pre-market
7.74
0.00%
After-hours
7.74
0.00%
Overnight
7.74
0.00%
- Market cap
- 511.23M
- P/E (TTM)i
- -14.60
- P/Bi
- -16.54
- EPSi
- -0.80
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on EOLS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 4.1 percentage points.
Institutional ownership
- Held by institutions
- 77.33% +4.14pp
- Institutions
- 184 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Hedge Fund35.22%
Mutual Fund31.10%
Individual/Insider10.89%
VC/PE Fund7.71%
Public Company2.13%
Private Company0.65%
Government Pension Fund0.19%
Insurance Company0.15%
Family Office/Trust0.11%
Other11.84%
Top holders as of 2025-12-31
Timothy Lynch
9.73% · 6.43M sh
Nantahala Capital Management, LLC
8.48% · 5.60M sh
BlackRock
7.33% · 4.84M sh
Soleus Capital Management, L.P.
5.27% · 3.48M sh
Braidwell LP
4.78% · 3.16M sh
Vanguard Capital Management, LLC
4.27% · 2.82M sh
Frazier Life Sciences Management, LP
3.98% · 2.63M sh
Perceptive Advisors LLC
3.72% · 2.46M sh
Millennium Management LLC
2.71% · 1.79M sh
State Street Global Advisors
2.57% · 1.70M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 28 buys · 22 sells
| Name | Role | Stake |
|---|---|---|
| Rui Avelar | Chief Medical Officer and Head of Research & Development | 0.41% |
| Vikram Malik | Chairperson | 0.37% |
| Brady Stewart | Independent Director | 0.13% |
| Sandra Beaver | Chief Financial Officer | 0.08% |
| David Gill | Independent Director | 0.06% |
| Albert White | Independent Director | 0.06% |
| Karah Parschauer | Independent Director | 0.05% |
| David Moatazedi | Chief Executive Officer | 0.00% |
| Simone Blank | Director | -- |
| Tomoko Yamagishi-Dressler | Chief Marketing Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-01 | David Moatazedi | Chief Executive Officer | Open Market Disposition | -105,108 | $9.04 |
| 2026-03-19 | Rui Avelar | Chief Medical Officer and Head of Research & Development | Automatic Disposition | -3,119 | $4.75 |
| 2026-03-19 | David Moatazedi | Chief Executive Officer | Automatic Disposition | -13,669 | $4.75 |
| 2026-03-16 | Rui Avelar | Chief Medical Officer and Head of Research & Development | Derivative Exercise and Sale | -8,804 | $4.89 |
| 2026-03-16 | Rui Avelar | Chief Medical Officer and Head of Research & Development | Automatic Disposition | -21,192 | $4.89 |
| 2026-03-16 | David Moatazedi | Chief Executive Officer | Derivative Exercise and Sale | -67,489 | $4.89 |
| 2026-03-16 | David Moatazedi | Chief Executive Officer | Automatic Disposition | -49,231 | $4.89 |
| 2026-02-16 | David Gill | Independent Director | Other Acquisition | +45,559 | -- |
| 2026-02-16 | Rui Avelar | Chief Medical Officer and Head of Research & Development | Other Acquisition | +94,913 | -- |
| 2026-02-16 | Rui Avelar | Chief Medical Officer and Head of Research & Development | Other Derivative Acquisition | +94,913 | -- |
| 2026-02-16 | Rui Avelar | Chief Medical Officer and Head of Research & Development | Other Derivative Acquisition | +138,649 | $4.39 |
| 2026-02-16 | Albert White | Independent Director | Other Acquisition | +45,559 | -- |
| 2026-02-16 | Vikram Malik | Chairperson | Other Acquisition | +45,559 | -- |
| 2026-02-16 | Karah Parschauer | Independent Director | Other Acquisition | +45,559 | -- |
| 2026-02-16 | David Moatazedi | Chief Executive Officer | Other Acquisition | +313,212 | -- |
| 2026-02-16 | David Moatazedi | Chief Executive Officer | Other Derivative Acquisition | +457,541 | $4.39 |
| 2026-02-16 | David Moatazedi | Chief Executive Officer | Other Derivative Acquisition | +626,424 | -- |
| 2026-02-16 | Brady Stewart | Independent Director | Other Acquisition | +45,559 | -- |
| 2026-02-16 | Tatjana Mitchell | Chief Financial Officer | Other Acquisition | +121,489 | -- |
| 2026-02-16 | Tatjana Mitchell | Chief Financial Officer | Other Derivative Acquisition | +121,489 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:55:56 · For reference only, not investment advice and not tailored to your situation.